Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial.

Area of Science:

• Neurology
• Pharmacology

Background:

• Chronic cerebellar ataxia is a debilitating condition with no current effective treatments.
• Riluzole's known pleiotropic effects suggest potential mechanisms to counteract ataxia progression.

Purpose of the Study:

• To evaluate the efficacy of riluzole as a symptomatic therapy for chronic cerebellar ataxia.
• To assess the impact of riluzole on the International Cooperative Ataxia Rating Scale (ICARS) in patients with diverse ataxia etiologies.

Main Methods:

• A randomized, double-blind, placebo-controlled pilot trial involving 40 patients with cerebellar ataxia.
• Patients received either riluzole (100 mg/day) or placebo for 8 weeks.
• Outcomes included changes in ICARS total and subscores and adverse event monitoring.

Main Results:

• Significantly more patients on riluzole achieved a 5-point decrease in ICARS score compared to placebo at both 4 and 8 weeks.
• Riluzole treatment led to a statistically significant reduction in mean ICARS total scores and major subscores.
• Adverse events were generally mild and sporadic, with no significant difference between groups.

Conclusions:

• Riluzole demonstrates potential as an effective symptomatic treatment for various forms of cerebellar ataxia.
• The study provides Class I evidence supporting riluzole's efficacy in reducing ataxia severity.